相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman et al.
CANCER DISCOVERY (2021)
Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
Yuta Maruki et al.
JOURNAL OF GASTROENTEROLOGY (2021)
Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012
Andrea A. Florio et al.
CANCER (2020)
A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3).
Mitesh J. Borad et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Melanie A. Krook et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Genomic basis for RNA alterations in cancer
Claudia Calabrese et al.
NATURE (2020)
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.
Siamak Daneshmand et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Robert Montal et al.
JOURNAL OF HEPATOLOGY (2020)
Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends
Mohamed M. Gad et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
Tanios S. Bekaii-Saab et al.
FUTURE ONCOLOGY (2020)
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
Angela Lamarca et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
Cholangiocarcinoma: Epidemiology and risk factors
Shahid A. Khan et al.
LIVER INTERNATIONAL (2019)
AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions
Milind Javle et al.
HEPATOBILIARY SURGERY AND NUTRITION (2019)
AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results
Matthew C. H. Ng et al.
HEPATOBILIARY SURGERY AND NUTRITION (2019)
Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma
Tao Wang et al.
HUMAN PATHOLOGY (2019)
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
Angela Lamarca et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).
Michele Droz Dit Busset et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes
Maeve A. Lowery et al.
CANCER (2019)
721PEfficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
M Droz Dit Busset et al.
ANNALS OF ONCOLOGY (2019)
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
BRITISH JOURNAL OF CANCER (2019)
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy
Melanie A. Krook et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States
Shiva Kumar R. Mukkamalla et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets
Hwajeong Lee et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management
Milind Javle et al.
CANCER (2016)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Rondell P. Graham et al.
HUMAN PATHOLOGY (2014)
Anchored multiplex FOR for targeted next-generation sequencing
Zongli Zheng et al.
NATURE MEDICINE (2014)
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Jeffrey S. Ross et al.
ONCOLOGIST (2014)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Chaitanya R. Churi et al.
PLOS ONE (2014)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with Survival
Sae-Byeol Choi et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform
Jiyoung Y. Cha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)